Document is current
Any future updates will be listed below
-
Authors
Bazyleva, Ekaterina https://orcid.org/0009-0000-7851-101X
De Schutter, Harlinde https://orcid.org/0000-0002-2031-984X
Croes, Romaric https://orcid.org/0009-0006-9159-3877
Deman, Frederik https://orcid.org/0000-0002-6925-571X
Roose, Emma
Van de Vijver, Koen https://orcid.org/0000-0002-2026-9790
Seegers, Paul https://orcid.org/0000-0002-7617-415X
Dendooven, Amélie https://orcid.org/0000-0002-9900-7952
-
Funding
Funding for this research was provided by:
AstraZeneca
Roche
- License Information
-
More Information
Article History
Received: 4 October 2024
Revised: 5 December 2024
Accepted: 13 December 2024
First Online: 7 January 2025
Declarations
:
: Van de Vijver has received advisory board and speaker fees (compensated to the institute) from GSK, Owkin, Exact Sciences, and AstraZeneca. Travel and accommodation were provided by GSK.
